Deletion or inhibition of myostatin in mammals has been demonstrated to markedly increase muscle mass by hyperplasia, hypertrophy, or a combination of both. Despite a remarkably high degree of conservation with the mammalian protein, the function of myostatin remains unknown in fish, many species of which continue muscle growth throughout the lifecycle by hyperplasia. Transgenic rainbow trout (Oncorhynchus mykiss) overexpressing follistatin, one of the more efficacious antagonists of myostatin, were produced to investigate the effect of this protein on muscle development and growth. P1 transgenics overexpressing follistatin in muscle tissue exhibited increased epaxial and hypaxial muscling similar to that observed in doublemuscled cattle and myostatin null mice. The hypaxial muscling generated a phenotype reminiscent of well-developed rectus abdominus and intercostal muscles in humans and was dubbed "six pack." Body conformation of the transgenic animals was markedly altered, as measured by condition factor, and total muscle surface area increased. The increased muscling was due almost exclusively to hyperplasia as evidenced by a higher number of fibers per unit area and increases in the percentage of smaller fibers and the number of total fibers. In several individuals, asymmetrical muscling was observed, but no changes in mobility or behavior of follistatin fish were observed. The findings indicate that overexpression of follistatin in trout, a species with indeterminate growth rate, enhances muscle growth. It remains to be determined whether the double muscling in trout is due to inhibition of myostatin, other growth factors, or both. myostatin; growth; transgenic; Oncorhynchus mykiss MUSCLE GROWTH IN ANIMALS is controlled by an array of factors, including myostatin, a member of the transforming growth factor-␤ (TGF-␤) superfamily (28). Myostatin is synthesized in muscle cells and inhibits proliferation and differentiation of myoblasts, limiting growth rate and muscle mass in mammals. The myostatin gene has been found in a variety of mammals, including bovine, murine, canine, and ovine species (22), and disruption of the gene has been demonstrated to markedly enhance muscle growth. The most striking examples of this phenomenon are the "double-muscled" Piedmontese and Belgian Blue breeds of cattle that carry mutations of the gene rendering the protein inactive (17, 28). Definitive evidence for the function of myostatin has been obtained in laboratory investigations in which marked hypertrophy and hyperplasia of muscle were produced in mice by inactivation of the gene, e.g., knockout (27), or inhibition of the protein, e.g., overexpression of the prodomain of myostatin, the primary binding protein of the bioactive protein (24, 44). Attempts to decipher the role of myostatin in lower vertebrates have been limited and/or largely unsuccessful, i.e., avian (20) and piscine (1) species.
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The ability of follistatin to bind and neutralize activin, and its role in reproductive development, has been well documented (41) . More recently, follistatin has been demonstrated to be a potent antagonist of other members of the TGF-␤ family, including myostatin (4) . Conclusive evidence of the capacity of follistatin to increase muscle growth has been obtained with transgenic mice overexpressing follistatin in which muscle mass was as much as 327% greater than in nontransgenic cohorts (24) . Still greater increases in muscle mass were observed in myostatin null mice overexpressing follistatin, suggesting that ligands other than myostatin might be involved in regulation of muscle growth (23) .
The myostatin gene/transcript has been identified in an array of fish species, including Atlantic salmon (31) , gilthead seabream (25) , channel catfish (21) , orange spotted grouper (11) , and barramundi (13) . Phylogenetic analysis suggests that the majority of osteichthyan species possess at least two myostatin genes, with salmonids having four paralogs (36) . Of note, conservation of the sequence of the bioactive peptide is remarkably high, with minimal differences among species of fish and with terrestrial vertebrates (32) . Despite the presence of myostatin across Ͼ27 species of fish, and demonstration of changes in transcript or protein levels during development (11, 16, 39) and under various conditions (7, 35, 38) , the function of this molecule remains largely unknown in piscine species. Several significant differences between muscle growth and development in mammals and fish make extrapolation of the function of myostatin difficult at best. In mammals, a single form of myostatin is largely restricted to muscle tissues (27) , whereas in fish most tissues express at least one paralog (34) . Muscle growth in many species of fish also continues throughout the life cycle by a combination of hyperplasia and hypertrophy, whereas in mammals muscle growth after birth is almost exclusively by hypertrophy. Finally, muscle structure in fish differs, with fast-twitch fibers comprising the vast majority of the musculature, most of this being a large mass along the longitudinal plane rather than discrete muscle groups (18) .
To gain insight into the function of follistatin, myostatin, and other potential factors regulating muscle growth and development in fish, transgenic trout overexpressing homologous follistatin were produced, and the effects on phenotype and muscle characteristics were investigated.
MATERIALS AND METHODS
Gametes and fish husbandry. Rainbow trout (Oncorhynchus mykiss) was selected as the model species based on the well-defined husbandry requirements, availability of eggs, and indeterminate growth of the animal. Ova and milt were obtained from two strains (Shasta and Arlee) of two-and three-year-old trout maintained at Ennis National Fish Hatchery (Ennis, MT). Fertilized eggs were hatched, and the larvae were reared at the University of Rhode Island Aquaculture Center following standard husbandry practices (33) . Juvenile rainbow trout were reared in 2-meter-diameter tanks supplied with flowing single-pass water ranging in temperature seasonally from 6 to 16°C and provided with supplemental aeration. Transgenic and nontransgenic fish (identified with an adipose fin clip) were reared communally at low rearing densities to ensure high rates of growth and optimum health. All research with animals was approved by the University of Rhode Island Institutional Animal Care and Use Committee under protocols AN01-04-031 and AN08-02-012.
Construct preparation. An amplicon of the rainbow follistatin transcript was generated by RT-PCR. Total RNA was isolated from epaxial muscle of juvenile rainbow trout, and 5 g were reverse transcribed using Moloney murine leukemia virus reverse transcriptase (New England Biolabs, Ipswich, MA) and oligo(dT) 18 primers. PCR of the cDNA was conducted using Accutaq LA DNA polymerase (Sigma, St. Louis, MO) and primers (Table 1) designed from the coding sequences (CDS) of salmon (accession no. DQ186633), zebrafish (accession no. NM131037), and catfish (accession no. AY574501). A 1,031-bp amplicon was purified by electrophoresis through a 1% agarose gel, and both strands of the follistatin CDS were sequenced using dideoxy terminators (URI Genomics and Sequencing Center). The purified cDNA was ligated in a blunt-end restriction site in a pSTBlue-1 vector (EMD Chemicals, Gibbstown, NJ) and subsequently excised from the plasmid using the restriction enzyme EcoRI and subcloned into a vector containing a 5Ј rat myosin light chain (rmylc) promoter, a 3Ј polyadenylation sequence, and the rmylc enhancer (15) . The construct was excised from the remainder of the plasmid vector and linearized by restriction digestion with NotI, followed by gel purification and resequencing for verification. Construct was quantified using a Nanodrop spectrometer (Thermo Fisher Scientific, Newark, DE) and diluted to a concentration of 200,000 copies/nl in molecular biology-grade water containing 4% green food coloring to allow visualization of the injection.
Microinjection. Glass injection needles were pulled from 1-mmdiameter thin-walled capillary tubes to a tip diameter of 5 m using a Pul-100 microprocessor-controlled vertical pipette puller [World Precision Instruments (WPI), Sarasota, FL]. The pipets were attached to the needle of a 5-l positive displacement syringe (Hamilton, Reno, NV) with melted surfboard wax (Mr. Zog's Sex Wax, Carpinteria, CA). A total volume of 5 nl was microinjected through the micropyle of each egg at a rate of 5 nl/s using a Micro 4 MicroSyringe pump controller (WPI).
A small quantity of milt was mixed with eggs in ovarian fluid for 5 min after which the fertilized eggs were rinsed and retained in 4 -6°C rainbow trout isotonic saline (in g/l: 9.04 NaCl, 0.24 KCl, and 0.34 CaCl 2) to prevent/reduce water hardening of the chorion. Eggs were microinjected with one million copies of linearized construct from 30 min to 3 h postfertilization and transferred to freshwater to incubate.
Transgenic screening. Upon attaining a weight of ϳ5 g, a small piece of fin tissue was excised from each individual and placed in 200 l of lysis buffer (50 mmol/l KCl, 10 mmol/l Tris, pH 8.8, 1.5 mmol/l MgCl 2, and 0.1% Triton X-100), boiled for 5 min, and treated with Proteinase K (6 units; Sigma) at 55°C for 1 h followed by 100°C for 10 min. The digested tissue was centrifuged at 12,000 g for 5 min, and 2 l of the supernatant were assayed by PCR using construct promoter (mylc 5 forward) and gene-specific primers (follistatin reverse; Table  1 ). Amplicons were electrophoresed on 1% agarose gels containing 0.01% ethidium bromide to visualize the presence or absence of the transgene.
Reverse transcription quantitative PCR. Reverse transcription quantitative PCR (RT-qPCR) was employed to monitor expression of the transgene. Tissue for measurement of follistatin RNA was excised from the same cross section used for histology (see below), and RNA was isolated with 96-well RNeasy plates (Qiagen). To eliminate contamination with genomic DNA, RNA samples were digested with DNaseI for 15 min before elution.
Expression of the follistatin construct was quantified using 50 ng of RNA in a one-step RT-qPCR SYBR green fluorescence assay (Stratagene, La Jolla, CA) with gene-specific primers (Table 1) . Assays were conducted with a MX4000 Real-Time PCR System (Stratagene) under the following conditions: reverse transcription for 30 min at 50°C, 95°C for 10 min, followed by 40 cycles of denaturation at 95°C for 30 s, annealing at 63°C for 1 min, extension, and read at 72°C for 30 s. All samples were assayed on the same plate in triplicate in conjunction with a duplicate eight-point standard curve of follistatin cDNA concentrations ranging from 10 to 100 million copies. A dissociation curve was generated for each amplified sample to ensure a single amplicon was produced. Triplicate controls lacking either reverse transcriptase or template were run in each assay. Because the primers amplified transcripts of both wild-type and recombinant follistatin, expression levels of follistatin in transgenic fish were compared with nontransgenic cohorts to ascertain the levels of total and recombinant protein transcripts. Each sample also was assayed in triplicate for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) using the same thermal regimen employed for follistatin with troutspecific GAPDH primers, but lacking the 72°C extension (Table 1) .
Muscle histology. Five each of the transgenic and control fish were killed with an overdose of tricaine methanesulfonate (Argent Chemicals, Redmond, WA), each fish was placed on a level acrylic tray with two metric rulers, and digital images were captured with a camera leveled perpendicular to the plane of the tray. Weight was measured to the nearest 0.1 g. A 5-mm-thick cross section (i.e., steak) was excised from each individual immediately anterior to the leading edge of the dorsal fin, and a digital image was recorded. Two 5 ϫ 5 mm cubes were excised from the epaxial section of the "steak," oriented to allow for a cross-sectional cut and inserted in cryosectioning embedding medium (Tissue tek; Thermo Fisher Scientific) in a stainless steel cassette. The tissue was frozen for 20 s in isopentane mixed with a magnetic stir bar and chilled in a bath of liquid nitrogen. Frozen tissue sections were wrapped in aluminum foil and stored in a sealed plastic bag at Ϫ80°C until processing. The tissue blocks were equilibrated to Ϫ9°C and cut at a thickness of 7 m with a Vibratome Ultrapro 5000 cryostat (St. Louis, MO). Tissue sections were mounted on slides coated with poly-L-lysine, air-dried, and stained with Gill's hematoxylin (2%) and eosin. Sections were examined, and digital images were captured with a Zeiss AxioPlan 2 light microscope (Thornwood, NY). The cross-sectional diameter of each fiber were measured as the shortest distance through the midpoint of all complete fibers in the field (128 -341 fibers/individual) using Image-Pro Plus software version 5.0.1 (Media Cybernetics, Bethesda, MD). Additionally, the number of fibers per unit surface area was determined by counting all fibers falling within a 540 ϫ 470 m rectangle (0.253 mm 2 ) randomly placed on the image of the muscle tissue section. Two separate nonoverlapping counts were made per section with three sections examined per individual (N ϭ 6). Myonuclei were quantified in the Follistatin forward 5Ј-GTT CGC TTC GCT GCT AGT GTC-3Ј Follistatin reverse 5Ј-TTA CTT ACA GTT GCA AGA TCC TGA ATG-3Ј Mylc 5 forward 5Ј-CAC CAC TGC TCT TCC AAG TGT CA-3Ј RT-qPCR forward 5Ј-GCA GAT CCA TAG GAG TAG CAT ATC-3Ј RT-qPCR reverse 5Ј-GTA GGT GGT GTT GTC GCT G-3Ј RT-qPCR GAPDH forward 5Ј-ACC ACT ACA ACC CAA TCA ACA GCA A-3Ј RT-qPCR GAPDH reverse 5Ј-TCG ATG AAG GGA TCG TTG ATG GC-3Ј
RT-qPCR, reverse transcription-quantitative PCR; GAPDH, glyceraldehyde-3-phosphate dehydrogenase. same sections and unit area. The mean number of fibers per unit area of each individual was used to calculate the number of fibers comprising the whole body cross section.
Morphometric and statistical analyses. To examine potential differences in body conformation the condition factor, a ratio of length to weight, was calculated using the formula (weight/length 3 ) ϫ 100. Length from the tip of the snout to the center of the boundary between the caudal peduncle and the caudal fin was determined from the digital images. Surface areas of the muscle cross section and the peritoneal cavity also were measured using Image Pro Plus software to allow determination of the total muscle surface area and total fiber number. Values from control and transgenic fish were compared using a Student's t-test except when data failed to exhibit normality or equal variances and a Mann-Whitney Rank Sum test was employed (Systat, San Jose, CA). All differences reported in the text are significantly different at a level of P Ͻ 0.05 or less.
RESULTS
Follistatin and rate of transgenesis. The follistatin CDS of rainbow trout (GenBank accession no. FJ185129) exhibited a high degree of identity with follistatin nucleotide sequences of Atlantic salmon (Salmo salar, 95%, NM_001123596), gilthead seabream (Sparus aurata, 83%, AY544167.1), olive flounder (Paralichthys olivaceous, 83%, EF219167.1), small mouth bass (Micropterus salmoides, 82%, EF128004.1), tilapia (Oreochromis mossambicus, 81%, DQ343148.1), and zebrafish (Danio rerio, 79%, AF084948.1) (Fig. 1A) . Identity of trout follistatin with the mouse (BC145945.1) and human nucleotide sequence (BC004107.2) was 72%. The trout CDS coded for a deduced protein with a theoretical molecular mass of 35.6 kDa and isoelectric point of 8.55. Some 4,941 newly fertilized eggs were microinjected during three different periods over two years, generating a total of 1,243 juveniles. Of these, 188 individuals (15% of the population), were found to have integrated the transgene into the genome (Fig. 1B) . Five P 1 transgenic and control individuals were killed and used for quantification of muscle fiber and cross sectional muscle area and assay of follistatin mRNA. All investigations were conducted with P 1 fish, since rainbow trout require two years to attain sexual maturation, and the fish produced here have not yet been spawned.
Expression of transgenes. Verification and quantification of transgene expression was determined by RT-qPCR of RNA obtained from muscle. The absolute copy number of follistatin transcripts is reported rather than a normalized ratio because GAPDH RNA concentration did not differ between groups and among individuals [control 25,146 Ϯ (SE) 752, transgenic 29,276 Ϯ 3,148]. The mean Ϯ SE follistatin transcript number for control fish was 2,422 Ϯ 422 (n ϭ 5) compared with transgenic fish with 43,117 Ϯ 23,593 (n ϭ 5) copies/50 ng total RNA (see Fig. 3A ) On average, follistatin transcript levels were 18-fold higher than in control fish. Assay of follistatin mRNA in heart, liver, spleen, and stomach tissue revealed that levels in transgenic fish were identical to controls, indicating that expression of the transgene was specific to skeletal muscle. Transcription and translation of the transgene was verified in cohort eggs microinjected with the CDS of green fluorescent protein (GFP) in the same construct. The presence of GFP was readily visible in the muscle tissue of both larvae and 2-yr-old fish ( Fig. 2A) .
Phenotype. Fish overexpressing follistatin exhibited a unique phenotype that we have dubbed "six pack." In all individuals expressing the transgene, the abdominal wall (hypaxial muscle) exhibited enhanced musculature that was visible in fish as small as 10 cm in length. The muscling ranged from slight indentations to prominent ridges that appeared to alternate in segments along the abdominal wall somewhat reminiscent of well-defined rectus abdominus or intercostal musculature in humans (Fig. 2B) . A marked increase in the quantity of epaxial musculature also was readily apparent. Examination of whole animal cross sections revealed increased muscle mass in both epaxial and hypaxial regions (Fig. 2B) . Quantification of the surface area of muscle in cross section revealed a significant increase in epaxial and hypaxial muscle surface area in relation to the total cross-sectional area (Fig. 3A) . In follistatin-overexpressing individuals, the percentage of epaxial muscle (49.5 Ϯ 3.5 vs. 45.5 Ϯ 2.2), hypaxial muscle (34.0 Ϯ 1.3 vs. 34 Ϯ 1.3), and peritoneal cavity volume (16.6 Ϯ 0.8 vs. 19.6 Ϯ 1.7) in the steak did not differ from control fish. In several individuals, a section of increased hypaxial muscling was unilateral, often continuing into the epaxial muscle. Accompanying the increased musculature was a change in body conformation, with condition factor in follistatin fish (1.72 Ϯ 0.05) significantly higher than in controls (1.50 Ϯ 0.01). The increased muscling did not affect mobility, feeding ability, or behavior of the fish. In first-generation fish approaching sexual maturation and exhibiting sexual dimorphism, "double muscling" was observed in both males and females. Muscle histology. Microscopic examination of cross sections of epaxial muscle revealed an increase in hyperplasia using two approaches. The number of fibers contained within six replicate 0.253-mm 2 areas/fish significantly increased from 53.8 Ϯ 1.4 in control fish to 61 Ϯ 1.6 in follistatin fish (Fig. 3B) . Extrapolation to the cross-sectional muscle surface area (Fig. 3C ) of each individual indicated a significantly higher number of fibers in follistatin fish (Fig. 3D) . No differences in the number of myonuclei per unit area were observed (Fig. 3E) . Similar results were observed by quantifying the frequency distribution of muscle fibers which showed a marked change in the fiber population (Fig. 4, A-C) . In control animals, the mean fiber diameter was 75.8 Ϯ 1.0 m (Fig. 4A) , whereas the diameter in follistatin trout was 66.4 Ϯ 0.9 m (Fig. 4B) . Statistical analysis revealed that the populations of muscle fibers were significantly different. Comparison of "normal" vs. "double" muscled epaxial and hypaxial areas of transgenic fish revealed no differences in the number of fibers per unit area or the size distribution of the fibers, i.e., both exhibited significant hyperplasia. Similarly, the transgene was expressed at similar levels in normal and double-muscled areas, i.e., follistatin mRNA quantity did not differ among regions of transgenic fish but was significantly different from control fish.
DISCUSSION
Overexpression of follistatin in rainbow trout generated a unique six-pack phenotype reminiscent of the double-muscling phenomenon observed in myostatin null or deficient cattle (17, 19) , mice (27, 42) , sheep (12) , and whippets (29) . Increases in both epaxial and hypaxial muscling were observed in trout exhibiting the six-pack phenotype. There are no reports of natural occurrences of fish with this phenotype or other type of excessive muscling similar to that observed in terrestrial animals. We hypothesize that the double muscling in trout results at least partly from inactivation of myostatin through the binding of follistatin. Follistatin and follistatin-related protein have been demonstrated to be potent antagonists of myostatin (4, 6, 37) , with the dissociation constant of murine follistatin for myostatin and activin reported to be 12.3 and 1.72 nM, respectively (30) . Indeed, overexpression of follistatin in transgenic mice resulted in a marked increase in musculature, greater than that observed in myostatin null mice, suggesting that follistatin may bind other growth/differentiation factors in addition to myostatin, including growth differentiation factor-11 (24) and activin (37) . Additional support for this theory was provided by experiments demonstrating further enhancement of muscle growth/mass in myostatin null mice overexpressing follistatin (23) . Myostatin is highly conserved, with the bioactive mature peptide of trout myostatin maintaining 99 -100% identity with myostatin of at least 20 species of fish and 88% identity with mice and humans at the amino acid level. Similarly, rainbow trout follistatin was found to possess a high degree of identity with other species of fish and with mice and humans, suggesting the potential for interaction of the two proteins. Recently, recombinant sea bream follistatin has been demonstrated to bind and inactivate sea bream myostatin using a mammalian luciferase construct reporter assay (34) . One hundred percent inhibition of myostatin binding was attained at a concentration of 1,000 ng follistatin/ml of culture media. These findings in mice and gilthead sea bream suggest that trout follistatin is capable of binding myostatin and generating the double-muscled phenotype observed in the present report. The six-pack phenotype has been observed only in the P 1 generation, and it remains to be seen whether it remains the same, is potentiated, or attenuated in the F 1 progeny. Unlike zebrafish that breed within 90 days of hatch, trout do not mature and spawn until two years of age, creating a significant lag period between generations. Of note, expression of the phenotype is not sex specific, since it appears equally expressed in male and female fish approaching maturation. The results of the current study do not eliminate the involvement of other endogenous factors in muscle growth in fish, including GDF-9 and -11 and activin. Preliminary investigations in our laboratory with transgenic trout containing a truncated activin IIb receptor, the receptor for myostatin and several other growth factors, reveal a similar double-muscling phenotype (data not shown).
Despite the identification of myostatin in an array of fish species, the mechanism of action of the molecule in muscle development and growth is unknown. Unlike the single form of myostatin found in mammals that is generally restricted to muscle tissue (24) , fish have at least two forms of myostatin (salmonids four), and distribution is ubiquitous (36) . In contrast to mammals that increase muscle mass almost exclusively by hypertrophy, fish increase muscle mass by constant recruitment of new muscle fibers throughout much of the life cycle. Indeed, in rainbow trout Ͻ5-50 cm in length, increases in muscle are almost exclusively related to hyperplasia (40) . At lengths Ͼ55 cm, further increases in muscle mass are primarily caused by hypertrophy of existing fibers. Because the primary function of myostatin in mammals appears to be negative regulation of muscle cell proliferation, the high rate of hyperplasia in fish and ubiquitous distribution of the molecule begs the question of whether myostatin performs the same function. Preliminary investigations with primary myosatellite cells isolated from rainbow trout suggest that myostatin might inhibit the proliferation of these cells (36) . The results of the present work in trout provide compelling evidence that reduction of levels of myostatin or other growth-regulating factors leads to increased hyperplasia and an increase in muscle mass in fish. Histological analysis of the follistatin transgenics indicated that increased musculature was caused almost exclusively by hyperplasia. This is of particular interest in light of the continued hyperplasia throughout much of the life cycle in rainbow trout and other species that exhibit indeterminate growth, a phenomenon by which the animal continues to grow as long as environmental conditions and nutritional status are suitable. Three previous investigations with zebrafish failed to demonstrate a significant effect of inhibition of myostatin on muscle mass and growth (1, 2, 43) . In one, Xu and coworkers (43) generated transgenic fish producing the myostatin prodomain to inhibit myostatin. Despite strong expression of the transgene, a limited effect on muscle hyperplasia was observed, with a 10% increase only in homozygous progeny for a limited period of the life cycle. In species such as zebrafish with determinate growth, muscle growth is characterized by stratified hyperplasia in which new fibers generate primarily from the proliferation zone below the skin (8) . In indeterminate growth, the vast majority of muscle growth occurs by mosaic hyperplasia throughout the musculature. In the present report, a marked increase in muscle mass by mosaic hyperplasia in follistatin-overexpressing trout was readily apparent.
The distinct six-pack pattern of muscling in the hypaxial region and additional epaxial muscling was common to all transgenics. As with the double-muscled cattle and myostatin null mice, the amount of muscling in any specific region varied to some degree among individuals. The phenotype in trout is all the more interesting considering that the anatomy of skeletal muscle of terrestrial mammals and fish differs markedly. Mam- malian muscle is arranged in discrete opposing groups, whereas the lateral body musculature of trout comprises some 60% of body weight and is divided into contiguous myotomes separated by the collagenous myosepta. The lateral musculature is comprised primarily of fast-twitch (white) with the slow-twitch fibers localized as a relatively thin superficial band under the lateral line in most species (18) . The mechanism responsible for development of the six-pack phenotype remains unclear. Of interest, the increased muscle mass of the peritoneal wall was sometimes unilateral, offset by normal muscling on the opposing side. One possible explanation for this phenomenon is the marked stimulation of muscle growth without a concurrent linear increase. Transgenic salmon carrying an additional copy of the growth hormone gene exhibit a striking increase in muscle mass accompanied by an increase in skeletal structure, i.e., length (14) . In the follistatin transgenics, the absence of a concurrent linear increase could cause "folding" of the muscle or, alternatively, localized increases in muscle mass. The higher condition factor in transgenic fish indicates a greater increase in girth than length. Of interest, the absence of a shift in the proportions of hypaxial and epaxial muscle in the transgenics supports consistent hyperplasia throughout the musculature. Although possible that this pattern of muscling could be related to mosaicism of the transgene, the presence of the phenotype to varying degrees in individuals produced from eggs and milt of multiple brood pairs and on different microinjection dates makes this less likely. Additionally, the mylc promoter used here produces a high level of expression, as evidenced by the quantity of GFP in muscle tissue, suggesting synthesis of sufficient quantities of follistatin to generate autocrine, paracrine, and endocrine effects. It also remains plausible that overexpression of follistatin during development might have impacted myotome formation. Finally, apparent differences in the quantity of muscle in some myotomes and regions might be related to differential expression of the transgene caused by an undetermined mechanism.
The findings reported here conclusively demonstrate that myostatin or related growth factors inhibited by follistatin have a role in muscle growth in fish. A recent report by Carpio and colleagues (10) suggests that administration of soluble activin IIB receptor, the receptor for myostatin, by immersion or injection stimulated an increase in growth and hyperplasia in goldfish and tilapia. Research with another nonmammalian vertebrate, i.e., early stage chicken embryos and isolated cells, suggests myostatin might affect myogenic cell identity and differentiation of satellite cells, but the findings are limited in scope (3, 20, 26) . Perhaps one of the more interesting points is that overexpression of follistatin was able to further accelerate hyperplastic growth of muscle tissue in trout, which already has a high rate of muscle hyperplasia. In mammals, which generally utilize hypertrophy to increase muscle mass, deletion (27) or inhibition of myostatin stimulated both hypertrophy and hyperplasia (45) , with hypertrophy predominating (5) . Related to this is the effect of myostatin inhibition on the population of myonuclei. One of the concerns raised in using myostatin inhibitors for treatment of muscle-wasting diseases in humans is potential depletion of the satellite cell population (5). Quantification of myonuclei in isolated murine muscle cells indicated no change in the myosatellite population with inhibition of myostatin, which the investigators attributed to hypertrophy rather than hyperplasia as the primary mechanism of the observed increase in muscle mass. In transgenic trout, in which the increase in muscle mass was almost exclusively via hyperplasia, no change in the number of myonclei was observed, suggesting constant renewal of the satellite cell population.
One of the questions remaining is whether follistatin is inhibiting myostatin, other muscle factors, or a combination of both. At this time, myostatin is the only known negative regulator of muscle growth. To the best of our knowledge, the presence of other members of the TGF-␤ superfamily potentially involved in growth, e.g., GDF-9 and -11, have yet to be reported in any species of fish with indeterminate growth rate; a GDF-11-like molecule has been reported in zebrafish (9) . Neither GDF-9 nor -11 has been found to have a negative regulatory effect on muscle tissue in mammals. Previous findings (23) and those in the current report do not discount the possibility that other negative muscle regulatory factors exist and could be related to the enhanced musculature observed in trout overexpressing follistatin.
It will be of interest to determine whether the increase in muscle mass observed in the P 1 follistatin individuals translates to an acceleration of growth rate in F 1 progeny. Measures of growth rate were not undertaken for this report, since the fish were all P 1 generation, gametes were derived from different parents on different dates, and the fish were reared in multiple tanks with weights and length obtained only at the time of death.
Perspectives and Significance
We believe these transgenic fish provide a unique model to examine muscle growth in an organism that, in contrast to mammals, exhibits a high level of hyperplasia throughout the life span. The large evolutionary distance between mammals and salmonids provides an opportunity to investigate divergent functions of follistatin and its role in muscle growth. From a translational perspective, the findings have utility for commercial aquaculture. Strategies to inhibit myostatin or other growth regulatory factors in commercially cultured species could lead to increased muscle mass, more rapid growth rate, or better feed conversion efficiency, providing a means for enhancing production.
